Scilex Holding (SCLX) Non Operating Income (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Non Operating Income of -$13.5 million for Q1 2026, down 841.53% year-over-year from $1.8 million in Q1 2025, and down 120.74% quarter-over-quarter from $65.0 million in Q4 2025.
Scilex Holding (SCLX) Non Operating Income (2022 - 2026) Analysis & Trends
Scilex Holding's Non Operating Income history runs 5 years deep, the most recent figure standing at -$13.5 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 841.53% year-over-year to -$13.5 million; the TTM figure through Mar 2026 stood at -$43.3 million (down 350.33% YoY), while the FY2025 annual figure was -$28.0 million, down 364.64% from the prior year.
- Non Operating Income for Q1 2026 stood at -$13.5 million, down from $65.0 million in the prior quarter.
- The five-year high for Non Operating Income was $65.0 million in Q4 2025, with the low at -$71.3 million in Q3 2025.
- The 5-year median for Non Operating Income is -$3.1 million (2023), against an average of -$736823.5.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income tumbled 1478.44% in 2023, then jumped 817.88% in 2024.
- Scilex Holding's Non Operating Income stood at $1.9 million in 2022, then plunged by 260.94% to -$3.1 million in 2023, then surged by 817.88% to $21.9 million in 2024, then jumped by 196.53% to $65.0 million in 2025, then plunged by 120.74% to -$13.5 million in 2026.
- Business Quant data shows SCLX's Non Operating Income at -$13.5 million in Q1 2026, $65.0 million in Q4 2025, and -$71.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | -85.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.48 Mn |
| Dec 31, 2025 | 64.99 Mn |
| Sep 30, 2025 | -71.31 Mn |
| Jun 30, 2025 | -23.52 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 21.92 Mn |
| Sep 30, 2024 | 15.53 Mn |
| Jun 30, 2024 | -21.96 Mn |
| Mar 31, 2024 | -4.90 Mn |
| Dec 31, 2023 | -3.05 Mn |
| Sep 30, 2023 | 3.28 Mn |
| Jun 30, 2023 | -3.84 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | 1.90 Mn |
| Sep 30, 2022 | 32.11 Mn |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | -334,000.00 |